S&P 500   3,940.27 (-0.03%)
DOW   33,660.30 (+0.19%)
QQQ   280.03 (-0.59%)
AAPL   141.44 (-1.03%)
MSFT   243.89 (-0.50%)
META   114.01 (-0.10%)
GOOGL   95.30 (-1.73%)
AMZN   87.89 (-0.41%)
TSLA   173.30 (-3.63%)
NVDA   158.18 (-1.06%)
NIO   12.31 (-7.02%)
BABA   87.66 (-4.14%)
AMD   69.68 (-0.84%)
T   19.29 (+0.63%)
MU   53.58 (-0.19%)
CGC   3.40 (-5.82%)
F   13.34 (+0.45%)
GE   85.96 (+0.80%)
DIS   92.12 (-0.18%)
AMC   6.68 (-1.04%)
PYPL   71.77 (-0.64%)
PFE   50.97 (+2.53%)
NFLX   304.98 (-0.19%)
S&P 500   3,940.27 (-0.03%)
DOW   33,660.30 (+0.19%)
QQQ   280.03 (-0.59%)
AAPL   141.44 (-1.03%)
MSFT   243.89 (-0.50%)
META   114.01 (-0.10%)
GOOGL   95.30 (-1.73%)
AMZN   87.89 (-0.41%)
TSLA   173.30 (-3.63%)
NVDA   158.18 (-1.06%)
NIO   12.31 (-7.02%)
BABA   87.66 (-4.14%)
AMD   69.68 (-0.84%)
T   19.29 (+0.63%)
MU   53.58 (-0.19%)
CGC   3.40 (-5.82%)
F   13.34 (+0.45%)
GE   85.96 (+0.80%)
DIS   92.12 (-0.18%)
AMC   6.68 (-1.04%)
PYPL   71.77 (-0.64%)
PFE   50.97 (+2.53%)
NFLX   304.98 (-0.19%)
S&P 500   3,940.27 (-0.03%)
DOW   33,660.30 (+0.19%)
QQQ   280.03 (-0.59%)
AAPL   141.44 (-1.03%)
MSFT   243.89 (-0.50%)
META   114.01 (-0.10%)
GOOGL   95.30 (-1.73%)
AMZN   87.89 (-0.41%)
TSLA   173.30 (-3.63%)
NVDA   158.18 (-1.06%)
NIO   12.31 (-7.02%)
BABA   87.66 (-4.14%)
AMD   69.68 (-0.84%)
T   19.29 (+0.63%)
MU   53.58 (-0.19%)
CGC   3.40 (-5.82%)
F   13.34 (+0.45%)
GE   85.96 (+0.80%)
DIS   92.12 (-0.18%)
AMC   6.68 (-1.04%)
PYPL   71.77 (-0.64%)
PFE   50.97 (+2.53%)
NFLX   304.98 (-0.19%)
S&P 500   3,940.27 (-0.03%)
DOW   33,660.30 (+0.19%)
QQQ   280.03 (-0.59%)
AAPL   141.44 (-1.03%)
MSFT   243.89 (-0.50%)
META   114.01 (-0.10%)
GOOGL   95.30 (-1.73%)
AMZN   87.89 (-0.41%)
TSLA   173.30 (-3.63%)
NVDA   158.18 (-1.06%)
NIO   12.31 (-7.02%)
BABA   87.66 (-4.14%)
AMD   69.68 (-0.84%)
T   19.29 (+0.63%)
MU   53.58 (-0.19%)
CGC   3.40 (-5.82%)
F   13.34 (+0.45%)
GE   85.96 (+0.80%)
DIS   92.12 (-0.18%)
AMC   6.68 (-1.04%)
PYPL   71.77 (-0.64%)
PFE   50.97 (+2.53%)
NFLX   304.98 (-0.19%)
NASDAQ:CRVS

Corvus Pharmaceuticals - CRVS Stock Forecast, Price & News

$1.00
-0.04 (-3.85%)
(As of 12/7/2022 10:06 AM ET)
Add
Compare
Today's Range
$1.00
$1.00
50-Day Range
$0.74
$1.04
52-Week Range
$0.70
$3.41
Volume
100 shs
Average Volume
128,408 shs
Market Capitalization
$46.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Corvus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
284.6% Upside
$4.00 Price Target
Short Interest
Healthy
0.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$35,200 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.92) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

211th out of 1,023 stocks

Pharmaceutical Preparations Industry

81st out of 501 stocks

CRVS stock logo

About Corvus Pharmaceuticals (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Stock News Headlines

See More Headlines
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Company Calendar

Last Earnings
11/03/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRVS
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+300.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-43,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.09 per share

Miscellaneous

Free Float
32,727,000
Market Cap
$46.55 million
Optionable
Not Optionable
Beta
0.97

Key Executives

  • Dr. Richard A. Miller M.D. (Age 71)
    Co-Founder, Pres, CEO & Chairman
    Comp: $303k
  • Dr. Peter A. Thompson FACP (Age 62)
    M.D., Co-Founder & Independent Director
    Comp: $47k
  • Mr. Leiv Lea (Age 68)
    Chief Financial Officer
    Comp: $449k
  • Dr. William Benton Jones Ph.D. (Age 56)
    Sr. VP of Pharmaceutical Devel.
    Comp: $400.4k
  • Dr. Erik J. Verner Ph.D. (Age 57)
    Co-Founder
  • Dr. James T. Rosenbaum M.D.
    Sr. VP of Research
  • Mr. Alan C. Mendelson Esq.
    Sec.













CRVS Stock - Frequently Asked Questions

Should I buy or sell Corvus Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRVS shares.
View CRVS analyst ratings
or view top-rated stocks.

What is Corvus Pharmaceuticals' stock price forecast for 2023?

3 analysts have issued 1 year price objectives for Corvus Pharmaceuticals' shares. Their CRVS share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 284.6% from the stock's current price.
View analysts price targets for CRVS
or view top-rated stocks among Wall Street analysts.

How have CRVS shares performed in 2022?

Corvus Pharmaceuticals' stock was trading at $2.41 at the beginning of 2022. Since then, CRVS stock has decreased by 56.8% and is now trading at $1.04.
View the best growth stocks for 2022 here
.

When is Corvus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our CRVS earnings forecast
.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) issued its quarterly earnings results on Thursday, November, 3rd. The company reported ($0.32) earnings per share for the quarter.

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.10%), Telemetry Investments L.L.C. (1.12%), Two Sigma Advisers LP (1.03%), Two Sigma Investments LP (0.92%), Bailard Inc. (0.09%) and Dimensional Fund Advisors LP (0.08%). Insiders that own company stock include Ecor1 Capital, Llc, Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc and Richard A Md Miller.
View institutional ownership trends
.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $1.04.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $48.42 million. The company earns $-43,240,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com.

This page (NASDAQ:CRVS) was last updated on 12/7/2022 by MarketBeat.com Staff